Pregnancy outcomes in women exposed to dihydroartemisinin-piperaquine in first trimester of pregnancy in Indonesia

A retrospective record linkage study

Rukhsana Ahmed¹, Kerryn A Moore², Theda Lukito³, Andre-Marie Touchatieu⁴, Stephanie Dellicour¹, Feiko ter Kuile¹, Richard N Price⁵, Julie A Simpson², Jeanne R Poespoprodjo⁶.

¹. Liverpool School of Tropical Medicine; ². Centre for Epidemiology & Biostatistics, University of Melbourne; ³. Clinesia, Jakarta; ⁴. Medicines for Malaria Venture; ⁵. Menzies School of Health Research & Charles Darwin University, Australia; ⁶. Timika Malaria Research Programme & Papuan Health & Development Community Foundation
Introduction to the study

Limited safety data restricts the use of artemisinins in first trimester of pregnancy

Indonesia is the first country to have introduced artemisinin based therapy & dihydroartemisinin-piperaquine (DP) for use in 2\textsuperscript{nd} and 3\textsuperscript{rd} trimester

More recently DP has been introduced for first trimester treatment of malaria in Indonesia

More than a decade of data on the use of DP is available in the two main hospitals in Timika, Papua

These are a valuable source to identify inadvertent or intentional use of DP in first trimester of pregnancy
Objectives

Primary aim was to obtain additional safety data on exposure of DP in the first trimester of pregnancy.

Specific objectives:

- To provide descriptive analysis of miscarriages, stillbirths and surface congenital anomalies in women exposed to DP in first trimester.
- To compare the risk of miscarriages, stillbirths and congenital anomalies in women treated with quinine and DP in first trimester.
STUDY DESIGN: A retrospective record linkage study
Data between 2006-2017 was extracted from electronic and manual records

Sample size of 1500 pregnancies
¬ Demographic, clinical and malaria diagnosis data was obtained from the linked records

¬ Date of delivery, data drug dispensed and estimated gestational age at delivery was used to estimate gestational age at time of malaria diagnosis and drug exposure
FINDINGS
Total malaria treatment any time in pregnancy and in first trimester

- Total women with malaria treatment anytime in pregnancy: n=9675
- Women treated for malaria in 1st trimester: N=1261, 12.0%
Number of exposures to DP & quinine in first trimester

DP

n=592

46.9%

QN

n=691

54.8%

Note: some women contribute to more than one pregnancy
Confirmed malaria episodes in 1st trimester

<table>
<thead>
<tr>
<th>Malaria Episodes</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 malaria episode</td>
<td>1035</td>
</tr>
<tr>
<td>2 malaria episodes</td>
<td>186</td>
</tr>
<tr>
<td>3 malaria episodes</td>
<td>33</td>
</tr>
<tr>
<td>4+ malaria episodes</td>
<td>7</td>
</tr>
</tbody>
</table>

- 82.0% confirmed episode
- 14.7% 2 confirmed episodes
- 2.6% 3 confirmed episodes
- 0.56% 4+ confirmed episodes
Birth outcomes in women exposed to antimalarials

No congenital anomalies were recorded in the hospital data

Stillbirth = gestational age ≥ 28 weeks
Miscarriage = gestational age ≤ 28 weeks

- Miscarriages:
  - 625, 6.5% (total exposure)
  - 42, 3.3% (1st trimester exposed)

- Stillbirths:
  - 104, 1.1% (total exposure)
  - 4, 0.3% (1st trimester exposed)

- Livebirths:
  - 8946, 92.4% (total exposure)
  - 1215, 96.4% (1st trimester exposed)
Conclusion

• It is work in progress with a prospective component following women exposed to DP till 8 weeks post-natal period

• Subsequent analysis will compare birth outcomes by drug exposure groups
Key messages

• The hospital records are a rich source of retrospective data to collect information on safety of antimalarial exposure in pregnancy

• Overall birth outcomes in women treated for malaria anytime in pregnancy were comparable to women who received treatment in first trimester of pregnancy

• A limitation of retrospective hospital data is that miscarriages maybe missed and surface congenital anomalies are not adequately documented

• Prospective component of this study will enable to provide additional information on miscarriages and surface anomalies.
Acknowledgments

• We thank the RSUD and RSMM Hospital Directors and medical records and other department teams for permitting access to past records

• Site team in Timika are thanked for their work

• Appreciate support from Helen Demarest, Maud Majeres Lugand and Helga Junker from MMV.